Spectrum Pharma: Buyout Rumors Persist Print
Friday, 07 August 2009 12:27

Unconfirmed rumors of a SPPI buyout were reported by TheFlyontheWall.  Shares of Spectrum Pharmaceuticals (Nasdaq: SPPI) jumped 7.81% in Friday morning trading.

 

 

TIMELINE

 

June 30, 2009

I first reported that Bayer Schering (BYERF.PK) could make an offer to acquire SPPI.

 

August 2, 2009

Reni J. Benjamin, Rodman and Renshaw biotech analyst, told Jonathan Moreland of RealMoney, “[c]ompany's like Bayer or Bristol-Myers (NYSE: BMY) may also look at the company more seriously if they are able to successfully market Zevalin.”

 

August 4, 2009

I reported SPPI rose 7.16% on speculation that it may be targeted for acquisition.

 

August 4, 2009

Adam Feuerstein of TheStreet.com (Nasdaq: TSCM) reported he was skeptical about an SPPI buyout.

 

August 6, 2009

SPPI announced that it acquired the 100% of the rights to RenaZorb® which is currently being studied in trials for hyperphosphatemia in patients with chronic kidney disease.

 

SPPI is scheduled to report Q2 earnings via webcast on August 13, 2009 at 12:00 PM ET.  Interested investors can access the webcast here.

 

CONCLUSION

 

SPPI’s move to acquire all of the rights to RenaZorb® indicates to me that Allergan (NYSE: AGN), who has been working to establish its urological drug division, may now be interested in bidding on SPPI. 

 

While this is merely speculation on my part, the possibilities certainly appear to be growing, rather than shrinking, along with SPPI’s share price.

 

Keep your eye on SPPI.

 

 

Disclosure: Long SPPI.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus